// App-Quantinova.ai

EP1199 : ELIGIBILITY FOR EMERGING THERAPIES IN SICKLE CELL DISEASE

Researchers

Presenter

  • Sona M Vora

Principal Investigators

  • Elizabeth R Jackson

  • Nicholas DR Denny

  • Nicole Paterson

  • Prisca Lux

  • Nomi BA Roy

  • Sanne Lugthart

Medical Centers

  • Department of Haematology,University Hospitals Bristol and Weston NHS Foundation Trust, Bristol UK,Bristol,United Kingdom

  • Department of Haematology,NIHR BRC Blood Theme,Oxford,United Kingdom

  • Department of Haematology,Oxford Myeloma Centre for Translational Research,Oxford,United Kingdom

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • School ofMedicine, University of Bristol, Bristol, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Sickle cell anemia

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxycarbamide

  • SelG1

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved